Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.
Haematologica|January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation studyEli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Blood Advances|December 24, 2019
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomesCaner Saygin, Ashwin Kishtagari, Ryan D Cassaday, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Blood Cancer Journal|April 4, 2026
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapyMasooma Shifa Rana, Sebastian Fernandez-Pol, Alexandria Jensen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Pageof 11